NEW YORK – Quest Diagnostics and Paige announced on Tuesday a collaboration leveraging Paige's machine learning expertise of pathology diagnostic data to discover biomarkers for cancer and other diseases.
The deal will include the use of digitized slides from Quest and combines its "leadership in advanced diagnostics, pathology subspecialty expertise, and national scale with Paige's leading AI-based software capabilities and proprietary data from millions of digitized pathology slides and associated therapy information," the firms said in a statement.
Quest and Paige aim to develop new software products for use by pathologists, oncologists, and other healthcare providers, following regulatory approval, to aid in disease diagnosis. Solid tumor cancers, such as prostate, breast, colorectal, and lung, will be the initial focus of the collaboration, which involves shared revenue based on the achievement of certain product and commercial milestones.
If regulatory approval is achieved, Quest will use the software products in its pathology operations. The partners will also jointly market the products, while Quest's pathologists will help define pathology workflows using the developed products to aid in diagnostic decision-making.